Oncology

Mirvetuximab soravtansine-gynx (Elahere) was first granted FDA accelerated approval in November 2022.

A blood-based cell-free DNA (cfDNA) test was able to find patients at increased risk of colorectal cancer (CRC), advanced neoplasia, and advanced precancerous lesions.

The approval was based on data from the phase 1/2 TRANSCEND CLL 004 study, in which the CAR T cell therapy demonstrated statistically significant complete response rates.

A clinical trial showed that nivolumab plus chemotherapy significantly improved overall survival and progression-free survival compared with a chemotherapy combination alone.

This is the fifth oncology indication for zanubrutinib in the United States.

The biosimilar represents a comprehensive, accessible, and high-quality treatment option for patients in the US treated with tocilizumab.

The agency approved denosumab-bddz under two brand names: Wyost and Jubbonti.

The FDA granted accelerated approval to amivantamab-vmjw in May 2021.

Reese Pharmaceutical’s ColoTest has a suggested retail price of $19.99 and will also be sold on major retail shelves later this spring.

The novel drug elranatamab-bcmm (Elrexfio) received accelerated FDA approval on August 14, 2023, for treating adults with relapsed or refractory multiple myeloma.

The FDA's decision represents a landmark approval of a tumor-derived cellular therapy in a solid tumor cancer.

Young women with breast cancer have a less favorable prognosis compared with older women. However, data on recent trends and period and cohort effects among young women are not well known.

As per US law Section 505(o)(4), the manufacturers are required to make the requested changes, respond with a modified version of the requested changes for review, or respond with a rebuttal within 30 days of the FDA's ask.

Biologic approvals ranged from gene therapies for hemophilia A to a cellular therapy to treat type 1 diabetes.

Study findings shed light on the disproportionate burden of type 2 diabetes (T2D) and colorectal cancer faced by individuals with low socioeconomic status and those of African American race.

Social determinants of health (SDOH), such as financial disparities or lack of insurance, create barriers to accessing breakthrough therapies like BTK inhibitors among patients with CLL and SLL.

Three posters presented at the 65th American Society of Hematology Annual Meeting and Exposition looked into the efficacy and safety of the therapies.

Data from the Surveillance, Epidemiology, and End Results (SEER) database were reviewed.

Six posters presented at the 65th American Society of Hematology Annual Meeting and Exposition looked at how treatments are impacting care for this patient population.

Understanding the adverse event profile of bispecific antibodies can aid treatment selection and improve patient outcomes.

Results of the phase 3 PERSEUS study were presented at the 2023 ASH Annual Meeting and Exposition.

In a conversation from this year's Healthcare Advocate Summit, Randy Falkenrath demystified the oncology medication management model and explained how specialty pharmacist can help patients access care.

Although early computed tomography (CT) screening was associated with improved cure rate for patients with lung cancer, less than 6% of the population that is eligible receives it.

The World Cancer Research Fund (WCRF) and American Institute for Cancer Research (AICR) Cancer Prevention Recommendations were updated in 2018 and encourage adopting healthy lifestyle habits.

Findings detailing long-term breast cancer outcomes for women who received a false-positive result underscore the significance of false-positive results as a critical public health issue.